Migraine trials in Netherlands

In Netherlands 7 Also abroad 249

7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Where
Nijmegen, 's-Gravenhage
Age
12 years to 17 years
People
420 worldwide
Run by
AbbVie
See details and how to joinNCT06810505 · EU 2024-513836-28-00
Phase 3Taking people
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Where
Amsterdam, Nijmegen, 's-Gravenhage, Terneuzen
Age
6 years to 17 years
People
450 worldwide
Run by
AbbVie
See details and how to joinNCT05711394 · EU 2022-501100-94-00
No phaseTaking people
The RECLAIM Study.
Where
Nieuwegein, Rotterdam
Age
18 years to 84 years
People
110 worldwide
Run by
Salvia BioElectronics
See details and how to joinNCT06450444
Phase 3Taking people
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Where
Leiden, Nijmegen, Zwolle
Age
18 years to 45 years
People
723 worldwide
Run by
Pfizer
See details and how to joinNCT06641466 · EU 2024-517121-10-00
Phase 4Taking people
(WHAT!) – RCT: Open-label randomized controlled trial for the effects of continuous daily use of ethinylestradiol/levonorgestrel (30/150 µg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related migraine and perimenopausal migraine
Where
Leiden
Age
18 years to 64 years
People
360
Run by
Leids Universitair Medisch Centrum (LUMC)
See details and how to joinNCT04007874 · EU 2024-517127-40-00
Phase 1Not yet taking people in Netherlands
Oxytocine and migraine
Where
Rotterdam
Age
18 years to 64 years
People
30
Run by
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2023-504690-21-00 · EU 2023-504690-21-00
Phase 3Enrolling by invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
Where
Amsterdam, Nijmegen, 's-Gravenhage, Terneuzen
Age
6 years to 17 years
People
650 worldwide
Run by
AbbVie
See details and how to joinNCT05707949 · EU 2022-501099-24-00